Original paper
Clinical trial research in focus: why do so many clinical trials fail in IPF?
Abstract
The overall prognosis of patients with idiopathic pulmonary fibrosis (IPF) is poor, with a 5-year survival of approximately 20%. The disease displays varying and unpredictable rates of progression making it difficult to determine prognosis in individual patients, especially at diagnosis. In 2014, two antifibrotic drugs (pirfenidone and nintedanib) have been shown to slow the pace of functional decline and disease progression, and are approved...
Paper Details
Title
Clinical trial research in focus: why do so many clinical trials fail in IPF?
Published Date
May 1, 2017
Volume
5
Issue
5
Pages
372 - 374
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History